- Home
- HTLD vs LXEO Comparison
HTLD vs LXEO Comparison
Compare HTLD & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTLD | LXEO |
|---|---|---|
| Founded | 1978 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 683.1M | 731.3M |
| IPO Year | 1995 | 2023 |
Fundamental Metrics
Financial Performance| Metric | HTLD | LXEO |
|---|---|---|
| Price | $11.03 | $6.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $9.80 | ★ $18.60 |
| AVG Volume (30 Days) | 624.0K | ★ 727.3K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.68% | N/A |
| EPS Growth | N/A | ★ 75.08 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,047,511,000.00 | $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.93 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.00 | $1.45 |
| 52 Week High | $12.13 | $10.99 |
Technical Indicators
Market Signals| Indicator | HTLD | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 50.66 | 32.15 |
| Support Level | $10.73 | $6.33 |
| Resistance Level | $12.13 | $7.72 |
| Average True Range (ATR) | 0.59 | 0.46 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 32.24 | 18.65 |
Price Performance
Historical ComparisonAbout HTLD Heartland Express Inc.
Heartland Express Inc is engaged in providing truckload services across the United States, Mexico, and Canada. These truckload services are asset-based transportation services in the dry van truckload market. The company offers truckload temperature-controlled transportation services, and Mexico logistics services. A majority of its customers represent the consumer goods, appliances, food products, and automotive industries.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.